DUBLIN–(BUSINESS WIRE)–The “Varicella Zoster (HHV-3) Infections – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report outlays comprehensive insights of present scenario and growth prospects across Varicella Zoster (HHV-3) Infections. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
Products covered by Phase
- Phase III, Phase II, Phase I
- Pre-clinical & Discovery
- Inactive (Discontinued and Dormant)
Overview of pipeline development activities for Varicella Zoster (HHV-3) Infections
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Varicella Zoster (HHV-3) Infections
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
Scope of the report
- Provides an overview of therapeutic pipeline activity for Varicella Zoster (HHV-3) Infections across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Varicella Zoster (HHV-3) Infections therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Varicella Zoster (HHV-3) Infections
Reasons to Buy
- Establish a comprehensive understanding of the current pipeline scenario across Varicella Zoster (HHV-3) Infections to formulate effective R&D strategies
- Assess challenges and opportunities that influence Varicella Zoster (HHV-3) Infections R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Varicella Zoster (HHV-3) Infections to enhance and expand business potential and scope
-
Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Key Topics Covered:
1. Report Introduction
2. Varicella Zoster (HHV-3) Infections – Disease Overview
3. Pipeline Outlook
- An Overview of Pipeline Products for Varicella Zoster (HHV-3) Infections
4. Comparative Analysis
5. Varicella Zoster (HHV-3) Infections Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Varicella Zoster (HHV-3) Infections Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Pipeline Analysis
- Pipeline Analysis by Route of Administration
- Pipeline Analysis by Stage and Route of Administration
- Pipeline Analysis by Molecule Type
- Pipeline Analysis by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Description
- Research and Development Studies
- Product Development Activities
- Reason for dormancy/discontinuation
Companies Mentioned
- Astellas Pharma Inc.
- Beijing Minhai Biotechnology Co. Ltd
- Beijing Tiantan Biological Products Co. Ltd.
- China National Pharmaceutical Group Corporation
- ContraVir Pharmaceuticals Inc.
- Epiphany Biosciences Inc.
- Foamix Pharmaceuticals Ltd.
- GeneOne Life Science Inc.
- GlaxoSmithKline Plc
- Green Cross Corporation
- Merck & Co. Inc.
- NAL Pharmaceuticals Ltd.
- ReceptoPharm Inc.
-
Sinovac Biotech Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jtaaga
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900